ERC000011
ENA-CHECKLIST
2022-08-12T00:14:59Z
ENA-FIRST-PUBLIC
2022-08-12T00:14:59Z
ENA-LAST-UPDATE
SAMEA110454452
External Id
WIS
INSDC center name
2022-08-12T00:14:59Z
INSDC first public
2022-08-12T00:14:59Z
INSDC last update
public
INSDC status
ERS12552482
SRA accession
E-MTAB-11884:Sample 687
Submitter Id
56
year
age
ArrayExpress
broker name
4994
cell id
common myeloid progenitor
cell_type
collected at AML diagnosis, prior to treatment
clinical information
human
common name
Protocols: peripheral blood (PB) and Bone Marrow (BM) obtained from the Rambam Bio-Bank, from AML patients from both diagnosis (Dx) and Rx were studied. Initially CD34+ enriched fraction was sorted into 2 populations of CD33+ and CD33- reflecting leukemic and normal progenitors, respectively. This was followed by sorting into different progenitor populations to yield homogenous populations from which subclones will be generated. This includes hematopoietic stem cell-multi potent progenitor (HSC/MPP), common myeloid progenitor (CMP), granulocyte myeloid progenitor (GMP) and multipotent/common lymphoid progenitor (MLP/CLP). each subpopulation was further sorted into single cell or alternatively undergone single cell subclone formation. Both single cells and single cell derived subclones were further sequenced. Samples that were grown in mouse are xenografts as interfemoral transplantation of hematopoietic stem and progenitor cells into Nod-scid immune suppressed female mice MDA based single cell WGA kit as described per sample in Biezuner et al. Genome Research. 2016. Targeted enrichment using duplex Molecular Inversion Probes protocol as described in (https://doi.org/10.1016/j.crmeth.2021.100054)
description
adult
developmental stage
acute myeloid leukaemia
disease
subclone
fraction
DiagnosisMLP33p
group label
immunophenotype
LCL440
individual
not applicable
isolate
Homo sapiens
organism
Homo sapiens
organism
blood
organism part
29173
samplereadsid
Homo sapiens
scientific_name
male
sex
Sample 687
title
xenograft